Ekso Bionics (NASDAQ:EKSO) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research report report published on Monday. The brokerage issued a hold rating on the stock.

A number of other brokerages have also recently issued reports on EKSO. Lake Street Capital cut their target price on Ekso Bionics from $2.50 to $2.00 and set a “buy” rating on the stock in a report on Tuesday, October 29th. HC Wainwright dropped their price objective on shares of Ekso Bionics from $10.00 to $9.00 and set a “buy” rating on the stock in a research note on Tuesday, October 29th.

Ekso Bionics Price Performance

Shares of NASDAQ EKSO opened at $0.76 on Monday. The firm has a market capitalization of $16.70 million, a P/E ratio of -1.17 and a beta of 1.47. The firm’s 50-day moving average price is $1.05 and its 200-day moving average price is $1.12. The company has a current ratio of 2.81, a quick ratio of 2.14 and a debt-to-equity ratio of 0.28. Ekso Bionics has a 1-year low of $0.72 and a 1-year high of $3.13.

Ekso Bionics (NASDAQ:EKSO) last issued its earnings results on Monday, October 28th. The company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.02). The firm had revenue of $4.13 million during the quarter, compared to the consensus estimate of $6.00 million. Ekso Bionics had a negative net margin of 62.95% and a negative return on equity of 83.09%. During the same period in the previous year, the firm earned ($0.24) earnings per share. Equities research analysts anticipate that Ekso Bionics will post -0.48 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Ekso Bionics stock. Kent Lake Capital LLC boosted its stake in Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 322.3% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 596,050 shares of the company’s stock after buying an additional 454,892 shares during the quarter. Kent Lake Capital LLC owned approximately 3.28% of Ekso Bionics worth $811,000 as of its most recent SEC filing. 6.42% of the stock is currently owned by institutional investors and hedge funds.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.